^
Association details:
| Biomarker: | TP53 mutation |
|---|---|
| Cancer: | Mantle Cell Lymphoma |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) + Gazyva (obinutuzumab) (CD20 inhibitor) + Brukinsa (zanubrutinib) (BTK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
Excerpt:
...Presence of TP53 mutation irrespective of variant allele frequency (TP53 cohort) OR Presence of p53 overexpression by immunohistochemistry defined as strong nuclear staining of >30% positive nuclei....
Trial ID:
Source:
Title:
Preliminary Safety and Efficacy from a Multicenter, Investigator-Initiated Phase II Study in Untreated TP53 Mutant Mantle Cell Lymphoma with Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen)
Published date:
11/04/2021
Excerpt:
Median follow up was 4 months (0 – 11 months). One pt has progressed and eleven pts remain on study in continued response. Of the 10 patients who have undergone disease restaging by Lugano criteria at C3 post BO, 80% (n=8/10) achieved PET-CR which has been maintained in 2 patients at C7....BOVen was well tolerated in untreated TP53 mutant MCL. The preliminary efficacy is promising in this high-risk subset of MCL...
DOI:
10.1182/blood-2021-151831
Trial ID:
